The Latest Cardiac and Vascular News
OXFORD, England and CHICAGO, Ill., June 24, 2025 /PRNewswire/ — Today, Brainomix, a pioneer in stroke artificial intelligence (AI) imaging solutions, and 3DR Labs, the market leader in medical imaging post-processing services, announced a new strategic partnership to support acute stroke…
Pivotal trial evaluates safety and efficacy of the Hēlo™ PE Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., June 23, 2025 /PRNewswire/ — E2 (Endovascular Engineering, Inc.), a medical device company advancing endovascular therapies, today announced…
BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ — Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction…
KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27. The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index results in automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index and the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. indexes. “We are honored to be included in the Russell indexes,” said Brian Webster, President and CEO of Kestra Medical Technologies. “The inclusion of Kestra in the Russell indexes following our March 2025 initial public offering is a significant milestone in our public company journey. As we continue to expand our presence across markets, we remain focused on protecting more patients at risk of sudden cardiac arrest and creating long-term value for our shareholders.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Immediate need to secure approximately €3.5 million to avoid insolvency at the end of June 2025 Total funding needs of around €35 million over the next 12 months Ongoing active exploration of financing options PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial […]
Data demonstrates MFI’s propriety software enables 15 minute immediate back-to-back Rest- Stress scanning with Flyrcadoä radiotracer SOUTH OGDEN, UT – June 20, 2025 –- MultiFunctional Imaging LLC (MFI) today announced the publication of data submitted to the Journal of Nuclear Cardiology (JNC), a leading peer-reviewed journal. The study validates MFI’s […]
Newest Addition in Line with the Company’s Stated Goal of Expanding its Clinical and Scientific Teams as it Progresses Development and Ultimate Commercialization of its SEAL™ Device to Treat Brain Aneurysms MILPITAS, Calif. , June 18, 2025 /PRNewswire/ — Galaxy Therapeutics, a privately…
BARCELONA – June 18, 2025 – ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union’s health, […]
BORDEAUX, France–(BUSINESS WIRE)–DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, today announced the close of a $6 million seed round to support the U.S. and global market launch of its FDA-approved cardiac imaging software, HeartFocus. “This funding moves us one step closer to a world […]
Lake Forest, CA – Crossroads Neurovascular, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K242392) for its groundbreaking PATH BGC™, a next-generation balloon guide catheter (BGC) designed to advance neurovascular intervention. With this clearance, PATH BGC becomes the world’s first BGC […]
